This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
REGNNegative Net Change ALNYPositive Net Change NVSNegative Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
by Zacks Equity Research
Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.
ARCTNegative Net Change GLPGPositive Net Change FULCNegative Net Change BVSNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Energy Fuels (UUUU) Enters Medical Isotope Market: Buy the Stock?
by Madhurima Das
Energy Fuels (UUUU) buys RadTran to leverage know-how to produce medical isotopes used in cancer treatments. Let us find out whether this can boost the stock.
CCJPositive Net Change UUUUPositive Net Change UECNegative Net Change
basic-materials biotechnology biotechs
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
by Zacks Equity Research
The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.
ILMNPositive Net Change LXRXNegative Net Change FULCNegative Net Change BVSNegative Net Change
biotechs
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
AZNPositive Net Change BMYNegative Net Change ILMNPositive Net Change ARCTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amicus (FOLD) Banks on Galafold, High Dependence a Concern
by Zacks Equity Research
Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.
ILMNPositive Net Change FOLDNo Net Change FULCNegative Net Change BVSNegative Net Change
biotechs
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
RDYPositive Net Change ILMNPositive Net Change ARCTNegative Net Change HLNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
by Zacks Equity Research
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
ILMNPositive Net Change NBIXPositive Net Change ARCTNegative Net Change XENENegative Net Change
biotechnology biotechs medical pharmaceuticals
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
by Zacks Equity Research
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy
by Zacks Equity Research
The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.
AZNPositive Net Change JNJPositive Net Change ARCTNegative Net Change FULCNegative Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
by Ekta Bagri
Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.
REGNNegative Net Change GILDNegative Net Change INCYNegative Net Change LQDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
by Zacks Equity Research
Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.
REGNNegative Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
by Zacks Equity Research
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
BMYNegative Net Change BMRNNegative Net Change KRYSNegative Net Change
biotechnology biotechs immuno-therapy pharmaceuticals
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
by Zacks Equity Research
Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.
SNYPositive Net Change BMYNegative Net Change KRYSNegative Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
by Andrew Rocco
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
NVOPositive Net Change LLYNegative Net Change SBUXPositive Net Change MCDPositive Net Change SHAKNegative Net Change
biotechnology biotechs
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
by Zacks Equity Research
The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.
UTHRPositive Net Change ARCTNegative Net Change LQDAPositive Net Change FULCNegative Net Change
biotechs medical pharmaceuticals
GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.
GSKNegative Net Change ILMNPositive Net Change FULCNegative Net Change BVSNegative Net Change
biotechs
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.
ILMNPositive Net Change ARCTNegative Net Change ABBVNegative Net Change GMABPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
by Sundeep Ganoria
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
VRTXNegative Net Change BEAMNegative Net Change EDITNegative Net Change CRSPNegative Net Change
biotechs crispr gene-therapy medical pharmaceuticals
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
by Ekta Bagri
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
GRFSNegative Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
by Andrew Rocco
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
APDNPositive Net Change TNXPNegative Net Change EBSPositive Net Change GOVXNegative Net Change VRAXNegative Net Change
biotechnology biotechs coronavirus vaccines
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
by Zacks Equity Research
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. However, overdependence on Livmarli for revenues is a concern.
ILMNPositive Net Change FULCNegative Net Change MIRMNegative Net Change
biotechs
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
by Zacks Equity Research
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
ILMNPositive Net Change ARCTNegative Net Change ANTXPositive Net Change FULCNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
by Zacks Equity Research
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
GSKNegative Net Change BMYNegative Net Change GILDNegative Net Change KRYSNegative Net Change
biotechs medical pharmaceuticals
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
by Zacks Equity Research
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.
NVSNegative Net Change INCYNegative Net Change SNDXPositive Net Change KRYSNegative Net Change
biotechs medical pharmaceuticals